cMET in NSCLC: Can we cut off the head of the Hydra? From the pathway to the resistance
Article
Van Der Steen, N, Pauwels, P, Gil-Bazo, I et al. (2015). cMET in NSCLC: Can we cut off the head of the Hydra? From the pathway to the resistance
. 7(2), 556-573. 10.3390/cancers7020556
Van Der Steen, N, Pauwels, P, Gil-Bazo, I et al. (2015). cMET in NSCLC: Can we cut off the head of the Hydra? From the pathway to the resistance
. 7(2), 556-573. 10.3390/cancers7020556
In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which are cell motility, invasion and metastasis. It also confers resistance against several currently used targeted therapies, e.g., epidermal growth factor receptor (EGFR) inhibitors. In this review, we will discuss the basic structure of cMET and the most important signaling pathways. We will also look into aberrations in the signaling and the effects thereof in cancer growth, with the focus on NSCLC. Finally, we will discuss the role of cMET as resistance mechanism.
